[go: up one dir, main page]

AR057695A1 - Procedimientos de administracion de vacunas contra calcivirus felinos, y tratamientos para inmunizar animales contra parvovirus felino y herpes virus felino - Google Patents

Procedimientos de administracion de vacunas contra calcivirus felinos, y tratamientos para inmunizar animales contra parvovirus felino y herpes virus felino

Info

Publication number
AR057695A1
AR057695A1 ARP060103269A ARP060103269A AR057695A1 AR 057695 A1 AR057695 A1 AR 057695A1 AR P060103269 A ARP060103269 A AR P060103269A AR P060103269 A ARP060103269 A AR P060103269A AR 057695 A1 AR057695 A1 AR 057695A1
Authority
AR
Argentina
Prior art keywords
vaccine
feline
feline calicivirus
isolated
nucleic acid
Prior art date
Application number
ARP060103269A
Other languages
English (en)
Inventor
David Earl Lowery
Sing Rong
Paul Mark Guimond
Paula Munns Clare
Cassius Mcallister Tucker
Thomas Jack Newby
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR057695A1 publication Critical patent/AR057695A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

Vacuna para inmunizar un gato contra virus felinos. Clon de ácido nucleico que codifica la proteína de la cápsida del calicivirus felino aislado. Vacuna viva o muerta, que comprende el calicivirus felino aislado, una vacuna de subunidad que comprende la proteína de la cápsida del calicivirus felino aislado, una vacuna de ácido nucleico que comprende un clon de ácido nucleico del calicivirus felino aislado, y una vacuna de vector de virus recombinante que comprende ácido nucleico que codifica la proteína de la cápsida del calicivirus felino aislado. Procedimiento para identificar un calicivirus felino util para producir una composicion de vacuna y para ensayos para diagnosticar gatos infectados con calicivirus felino. También se describe un procedimiento para inmunizar animales, especialmente gatos, contra una enfermedad, en particular contra calicivirus felino (FCV). El procedimiento incluye administrar a un gato cantidades terapéuticamente eficaces de primera y segunda vacunas de FCV. La primera vacuna se administra por vía oral o parenteral (por vía subcutánea, por vía intramuscular, y similares). La segunda vacuna se administra por vía oral u oronasal N días después de la administracion de la primera vacuna, en el que N es un numero entero de 3 a 120, ambos inclusive. También puede darse una tercera administracion de vacuna. Procedimientos y materiales para tratar e inmunizar animales con vacuna, y en articular gatos contra FPV o Parvovirus Felino, que también se denomina Panleucopenia o FPL y contra otra enfermedad, FHV o Herpesvirus Felino, que también se denomina Virus de la Rinotraqueítis Felina.
ARP060103269A 2005-07-28 2006-07-27 Procedimientos de administracion de vacunas contra calcivirus felinos, y tratamientos para inmunizar animales contra parvovirus felino y herpes virus felino AR057695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70310905P 2005-07-28 2005-07-28

Publications (1)

Publication Number Publication Date
AR057695A1 true AR057695A1 (es) 2007-12-12

Family

ID=37198861

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103269A AR057695A1 (es) 2005-07-28 2006-07-27 Procedimientos de administracion de vacunas contra calcivirus felinos, y tratamientos para inmunizar animales contra parvovirus felino y herpes virus felino

Country Status (17)

Country Link
US (2) US7790169B2 (es)
EP (2) EP2292250A1 (es)
JP (3) JP5318573B2 (es)
KR (1) KR20080025197A (es)
CN (4) CN101563096A (es)
AR (1) AR057695A1 (es)
AT (1) ATE496629T1 (es)
AU (2) AU2006273753B2 (es)
BR (1) BRPI0614119B8 (es)
CA (1) CA2617341C (es)
DE (1) DE602006019878D1 (es)
ES (1) ES2357679T3 (es)
MX (1) MX2008001326A (es)
NO (1) NO20080046L (es)
RU (1) RU2008102930A (es)
TW (1) TW200740454A (es)
WO (1) WO2007012944A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012944A2 (en) * 2005-07-28 2007-02-01 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
DK2542260T3 (en) * 2010-03-05 2016-06-06 Intervet Int Bv Recombinantly weakening parvovirus
JP2012044910A (ja) * 2010-08-25 2012-03-08 Chubu Food & Environmental Safety Center Co Ltd ネコカリシウイルス遺伝子の発現用ベクター及びこれを用いたウイルスの製造方法
WO2012030720A1 (en) * 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
EP2744894A4 (en) * 2011-08-18 2015-04-22 Ycine Llc PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST
CN103773739B (zh) * 2013-03-01 2016-06-15 上海启盛生物科技有限公司 一种猫泛白细胞减少症病毒减毒疫苗株及其应用
CN103276106B (zh) * 2013-05-03 2014-09-03 中国农业科学院哈尔滨兽医研究所 用于同时检测猫泛白细胞减少症病毒、猫杯状病毒和猫疱疹病毒1型的多重pcr引物组
CA2976243C (en) 2015-02-10 2023-10-31 Ohio State Innovation Foundation Chlamydia-activated b cell platforms and methods thereof
CA2996143A1 (en) * 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
CA3004924A1 (en) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
BR112018012642A2 (pt) * 2015-12-23 2018-12-04 Intervet Int Bv vacina de calicivírus felino
CN106190988B (zh) * 2016-07-13 2020-01-07 长春西诺生物科技有限公司 猫嵌杯病毒ch-jl5株灭活疫苗
CN108362877A (zh) * 2018-01-24 2018-08-03 中国农业科学院兰州畜牧与兽药研究所 猫杯状病毒荧光免疫层析检测试纸条及其制备方法
CN108371710B (zh) * 2018-01-30 2021-09-21 长春西诺生物科技有限公司 猫传染性鼻结膜炎和猫泛白细胞减少症二联疫苗及制备方法
CN112921122A (zh) * 2021-03-26 2021-06-08 广西大学 猫常见病毒多重pcr快速检测试剂盒及其引物组
CN113943354B (zh) * 2021-10-11 2022-09-06 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种重组猫疱疹病毒gB蛋白抗原及其在抗体诊断和疫苗制备中的应用
CN113943830A (zh) * 2021-10-14 2022-01-18 广州悦洋生物技术有限公司 一种用于同时检测猫细小病毒、猫疱疹病毒1型和猫杯状病毒的引物探针组及试剂盒
CN114634564B (zh) * 2022-04-18 2023-04-04 北京华驰千盛生物科技有限公司 猫用三联卵黄抗体、制剂及制备方法与用途
CN114874997B (zh) * 2022-05-26 2023-05-23 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 猫杯状病毒
CN115058541B (zh) * 2022-06-17 2023-05-09 湖南大圣宠医生物科技有限公司 检测猫口炎病原体并分型的组合物、试剂盒、方法及其用途
CN116200347A (zh) * 2022-09-19 2023-06-02 中国农业科学院上海兽医研究所 一种gI、gE和TK三基因缺失株猫疱疹病毒疫苗及其应用
CN116042679B (zh) * 2022-12-13 2025-11-28 浙江大学 一种表达猫杯状病毒VP1蛋白的mRNA疫苗及其制备方法
CN115969967B (zh) * 2023-01-10 2023-08-04 浙江大学 用于预防猫鼻气管炎、猫杯状病毒病、猫泛白细胞减少症的三联mRNA疫苗及其制备方法
CN116655784B (zh) * 2023-06-30 2025-02-07 深圳赫兹生命科学技术有限公司 基于vp1蛋白的检测猫杯状病毒的抗体及其应用
CN117143924B (zh) * 2023-09-11 2024-03-22 华中农业大学 共表达猫杯状病毒和猫细小病毒抗原蛋白的重组猫疱疹病毒及其活载体疫苗和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
US3937312A (en) 1974-10-04 1976-02-10 The Torrington Company Retainer for roller clutch
US3937812A (en) 1974-11-21 1976-02-10 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US3944469A (en) 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4522810A (en) * 1982-12-09 1985-06-11 The Regents Of The University Of California Feline calicivirus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4786589A (en) 1986-08-18 1988-11-22 Huntington Medical Research Institute Immunoassay utilizing formazan-prelabeled reactants
US5169789A (en) 1986-12-03 1992-12-08 New Horizons Diagnostics Corporation Device and method for self contained solid phase immunodiffusion assay
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US5620845A (en) 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5716822A (en) 1989-07-21 1998-02-10 Pharmacia & Upjohn Company Feline calicivirus capsid gene and protein
EP0484382B1 (en) 1989-07-21 1995-03-08 The Upjohn Company Feline calicivirus capsid protein and nucleotide sequence
US5226313A (en) * 1989-12-15 1993-07-13 Murata Mfg. Co., Ltd. Body fluid excretion measurement apparatus for medical application
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
KR910014706A (ko) 1990-01-10 1991-08-31 원본미기재 세척이 필요없는 개량된 이뮤노어세이(immunoassay)장치
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US6241989B1 (en) * 1991-07-09 2001-06-05 Cornell Research Foundation, Inc. Recombinant multivalent viral vaccine
US5725863A (en) 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
US6010703A (en) 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
US5695928A (en) 1993-12-10 1997-12-09 Novartis Corporation Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction
US5561064A (en) 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
US6231863B1 (en) * 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
AU5329300A (en) 1999-06-10 2001-01-02 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
US6534066B1 (en) * 1999-07-16 2003-03-18 Merial Inactivated vaccine against feline calicivirosis
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
FR2796282B1 (fr) * 1999-07-16 2001-10-26 Merial Sas Vaccin inactive contre la calicivirose feline
CA2513458C (en) 2003-03-14 2013-01-22 The Regents Of The University Of California Virulent systemic feline calicivirus
WO2005080416A1 (en) * 2004-01-20 2005-09-01 Pharmacia & Upjohn Company Llc Feline calicivirus vaccines
WO2007012944A2 (en) * 2005-07-28 2007-02-01 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus

Also Published As

Publication number Publication date
WO2007012944A3 (en) 2007-04-26
CN101563096A (zh) 2009-10-21
JP5847116B2 (ja) 2016-01-20
EP1912665B1 (en) 2011-01-26
CN103550767B (zh) 2017-04-19
TW200740454A (en) 2007-11-01
CN103550768B (zh) 2016-01-20
BRPI0614119B8 (pt) 2017-04-11
EP1912665A2 (en) 2008-04-23
JP2009502900A (ja) 2009-01-29
WO2007012944A2 (en) 2007-02-01
JP5859923B2 (ja) 2016-02-16
CN103550768A (zh) 2014-02-05
ATE496629T1 (de) 2011-02-15
DE602006019878D1 (de) 2011-03-10
KR20080025197A (ko) 2008-03-19
US20070031454A1 (en) 2007-02-08
AU2006273753B2 (en) 2010-06-24
CA2617341A1 (en) 2007-02-01
US8444997B2 (en) 2013-05-21
US20110052619A1 (en) 2011-03-03
HK1211864A1 (en) 2016-06-03
AU2006273753A2 (en) 2008-04-03
JP2012211161A (ja) 2012-11-01
ES2357679T3 (es) 2011-04-28
CA2617341C (en) 2011-03-29
BRPI0614119A2 (pt) 2011-03-09
AU2010212382B2 (en) 2013-06-06
RU2008102930A (ru) 2009-07-27
EP2292250A1 (en) 2011-03-09
CN104758927B (zh) 2017-11-21
JP5318573B2 (ja) 2013-10-16
CN103550767A (zh) 2014-02-05
MX2008001326A (es) 2008-03-19
JP2013224295A (ja) 2013-10-31
NO20080046L (no) 2008-01-30
WO2007012944A9 (en) 2008-10-16
AU2010212382A1 (en) 2010-09-09
CN104758927A (zh) 2015-07-08
BRPI0614119B1 (pt) 2016-10-11
US7790169B2 (en) 2010-09-07
AU2006273753A1 (en) 2007-02-01
HK1194303A1 (zh) 2014-10-17

Similar Documents

Publication Publication Date Title
AR057695A1 (es) Procedimientos de administracion de vacunas contra calcivirus felinos, y tratamientos para inmunizar animales contra parvovirus felino y herpes virus felino
ES2778425T3 (es) Variante de la proteína ORF2 del PCV2 y partículas similares a virus compuestas por esta
Dean et al. Pathogenesis of rabies
JP6824177B2 (ja) 豚流行性下痢ウイルス株及びそれから得られる免疫原性組成物
WO2003003941A3 (en) One dose vaccination with mycoplasma hyopneumoniae
EP4141022A1 (en) Feline calicivirus vaccine
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
US20120251564A1 (en) Reovirus compositions and methods of use
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
ES2424847T3 (es) Genes del virus de la fiebre aftosa que expresan avipox recombinantes
Wernery et al. Experimental camelpox infection in vaccinated and unvaccinated dromedaries
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
Lu et al. Virus-like particle vaccine with B-cell epitope from porcine epidemic diarrhea virus (PEDV) incorporated into hepatitis B virus core capsid provides clinical alleviation against PEDV in neonatal piglets through lactogenic immunity
AR047581A1 (es) Vacunas de calicivirus felino
PT1734992E (pt) Vacinas melhoradas de fcv inactivado
AU2018275790B2 (en) Genetically attenuated nucleic acid vaccine
US20060160101A1 (en) Inactivated FCV vaccines
EP2053056B1 (en) Dendrimeric peptide construct for the prevention of foot-and-mouth disease in animals
CA2439872A1 (en) Leporipox-based vector vaccines
CO5721019A2 (es) Aislados y vacunas antigenicos de virus de bursitis infecciosa
KR100790801B1 (ko) 동물용 불활화 백신의 제조방법
Bhutia et al. The recent developmental platforms and potential targets of SARS CoV-2 vaccines: a comprehensive review
Awais et al. Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review
JP2008534598A (ja) 免疫原の干渉を克服するための、慣習的なワクチンと組み合わせたｄｎａワクチンの使用

Legal Events

Date Code Title Description
FB Suspension of granting procedure